Pfizer’s third quarter results reflected ongoing challenges in its COVID-19 franchise, but management pointed to solid growth ...

"By combining precise tumour targeting with an immunotherapy payload, Daiichi Sankyo is exploring a new way to harness the ...

On Monday, 10 November 2025, the healthcare world was abuzz as two pharmaceutical giants, Pfizer and Novo Nordisk, fiercely ...

Novo Nordisk has reported the mixed midphase results behind its push to enter a heart disease market s | Novo Nordisk has ...

The bidding war between Pfizer ( PFE) and Novo Nordisk ( NVO) over obesity drug developer Metsera ( MTSR) finally ended over ...

For most of Big Pharma, drug discounts have largely been about damage control. After months of tariff threats and talk of ...

That likely only increases the appetite of biotech investors to bet on the next thing. But keep in mind the deal offers some ...

As you might expect, the competition to win a share of the expanding GLP-1 market is fierce right now, with giants Novo ...

Pfizer Inc. ( PFE) Discusses Clinical Development Strategy for 4404 Bispecific Antibody in Oncology November 10, 2025 8:30 AM EST ...

By now, you know that the COVID-19 vaccine is the best way to protect against severe COVID infections and reduce your chances ...

Background Immunogenicity to SARS-CoV-2 vaccination in patients with SLE varies by vaccine type and immune-modulating therapy. However, data in Southeast Asian populations, especially among Thai ...

Lilly will also gain certain rights to MeiraGTx’s proprietary riboswitch technology for use in gene editing in the eye. Under ...